Document Detail

Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis.
MedLine Citation:
PMID:  21040935     Owner:  NLM     Status:  In-Data-Review    
Hypoadiponectinemia might represent a risk factor for nonalcoholic fatty liver disease (NAFLD). We performed a systematic review and meta-analysis to evaluate the serum total adiponectin levels in patients with simple nonalcoholic fatty liver (NAFL), those with nonalcoholic steatohepatitis (NASH), and controls. Data were extracted from PubMed, EMBASE, and Cochrane Central Register of Controlled Trials electronic databases (up to December 2009). The main outcome was the weighted mean differences (WMDs) in adiponectin between comparison groups. Twenty-eight studies were included in the systematic review. A meta-analysis of 27 studies that reported data on 2243 subjects (698 controls and 1545 patients with NAFLD) was performed. Controls had higher serum adiponectin compared with NAFL patients (12 studies, random-effects WMD [95% confidence interval {CI}] = 3.00 [1.57-4.43], I(2) = 80.4%) or NASH patients (19 studies, random-effects WMD [95% CI] = 4.75 [3.71-5.78], I(2) = 84.1%). The NASH patients demonstrated lower adiponectin compared with NAFL patients (19 studies, random-effects WMD [95% CI] = 1.81 [1.09-2.53], I(2) = 71.7%). By performing a meta-regression analysis, body mass index, age, sex, and type 2 diabetes mellitus failed to account for heterogeneity. However, the performance of liver biopsy on controls had significant effect on the outcome and accounted for 76.7%, 85.5%, and 22.8% of the between-study variance for comparisons between controls vs NAFLD, NAFL, and NASH patients, respectively. Based on liver histology, serum adiponectin levels are similar in NAFL patients and controls, but hypoadiponectinemia may play an important pathophysiological role in the progression from NAFL to NASH.
Stergios A Polyzos; Konstantinos A Toulis; Dimitrios G Goulis; Christos Zavos; Jannis Kountouras
Related Documents :
19471855 - Efficacy and safety of atazanavir in patients with end-stage liver disease.
6222845 - Clinical pharmacology of the anticancer polypeptide neocarzinostatin.
3856935 - Chronic active hepatitis. experience from a norwegian reference hospital during a decade.
539335 - Serum activity of ornithine carbamoyl transferase in patients operated with jejunoileal...
8194955 - Gemeprost in the management of second trimester intrauterine fetal death.
24411585 - Quantifying the burden of disease and perceived health state in patients with hereditar...
Publication Detail:
Type:  Journal Article     Date:  2010-10-30
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  60     ISSN:  1532-8600     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  United States    
Other Details:
Languages:  eng     Pagination:  313-26     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 546 42 Thessaloniki, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hepatocyte growth factor has a role in the amelioration of diabetic vascular complications via autop...
Next Document:  The association between the metabolic syndrome and alanine amino transferase is mediated by insulin ...